PRIME MEDICINE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.48 USD | -0.31% |
|
-6.43% | -26.86% |
| May. 20 | HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target | MT |
| May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 1,609 | 817.2 | 749.2 | - | - |
| Enterprise Value (EV) 1 | 1,450 | 695.5 | 672.3 | 544 | 366.5 |
| P/E ratio | -4.43 x | -4.06 x | -3.86 x | -4.29 x | -4.34 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 169 x | 205 x | 103 x |
| EV / Revenue | - | - | 151 x | 149 x | 50.3 x |
| EV / EBITDA | -12.7 x | -3.42 x | -3.33 x | -2.22 x | -1.18 x |
| EV / FCF | -9.8 x | -3.99 x | -3.5 x | -2.62 x | -1.63 x |
| FCF Yield | -10.2% | -25% | -28.6% | -38.2% | -61.4% |
| Price to Book | 5.71 x | 6.06 x | 3.8 x | 3.67 x | 2.56 x |
| Nbr of stocks (in thousands) | 86,611 | 92,230 | 115,625 | - | - |
| Reference price 2 | 18.58 | 8.860 | 6.480 | 6.480 | 6.480 |
| Announcement Date | 3/9/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 4.442 | 3.653 | 7.284 |
| EBITDA 1 | - | -114.3 | -203.5 | -201.7 | -245.3 | -310.7 |
| EBIT 1 | - | -116.5 | -204.8 | -202.5 | -227 | -259.1 |
| Operating Margin | - | - | - | -4,557.73% | -6,214.31% | -3,557.67% |
| Earnings before Tax (EBT) 1 | -165.9 | -122.8 | -198.4 | -192.5 | -214.5 | -232.1 |
| Net income 1 | -165.4 | -142 | -198.1 | -192.6 | -214.6 | -231.8 |
| Net margin | - | - | - | -4,335.1% | -5,874.05% | -3,181.9% |
| EPS 2 | - | -4.190 | -2.180 | -1.677 | -1.509 | -1.492 |
| Free Cash Flow 1 | - | -147.9 | -174.1 | -192.2 | -207.6 | -225 |
| FCF margin | - | - | - | -4,327.49% | -5,682.73% | -3,089.43% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 3/7/22 | 3/9/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | 0.591 | 1.358 | 0.3 | 0.3364 | - | - |
| EBITDA 1 | - | - | -38.98 | - | - | -63.39 | -47.03 | -48.04 | -48.48 | -48.94 | - | - |
| EBIT 1 | -31.66 | -38.69 | -40.03 | -45.26 | -51.46 | -68.04 | -48.34 | -49.4 | -50.81 | -52.32 | -62.07 | -50.96 |
| Operating Margin | - | - | - | - | - | - | -8,179.53% | -3,637.03% | -16,937.55% | -15,554.13% | - | - |
| Earnings before Tax (EBT) 1 | - | -39.47 | -39.6 | -42.35 | -50.82 | -65.64 | -45.63 | -48.12 | -48.95 | -49.68 | -50.65 | -50.96 |
| Net income 1 | - | -40.6 | -39.4 | -42.38 | -50.71 | -65.64 | -45.76 | -48.13 | -48.97 | -49.7 | -50.65 | -50.96 |
| Net margin | - | - | - | - | - | - | -7,742.98% | -3,543.2% | -16,321.83% | -14,775.23% | - | - |
| EPS 2 | -1.610 | - | -0.4400 | -0.4700 | -0.5500 | -0.7200 | -0.4400 | -0.4064 | -0.4119 | -0.4084 | -0.3900 | -0.3900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/22 | 3/9/23 | 5/11/23 | 8/7/23 | 11/3/23 | 3/1/24 | 5/10/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | - | 159 | 122 | 77 | 205 | 383 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | - | -148 | -174 | -192 | -208 | -225 |
| ROE (net income / shareholders' equity) | - | -177% | -88.2% | -138% | -134% | -98.2% |
| ROA (Net income/ Total Assets) | - | -42.9% | -71.5% | -78.6% | -65.3% | -64.2% |
| Assets 1 | - | 331.1 | 277.1 | 245 | 328.4 | 361 |
| Book Value Per Share 2 | - | 3.250 | 1.460 | 1.710 | 1.760 | 2.530 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 16.1 | 8.72 | 8.41 | 9.37 | 10.9 |
| Capex / Sales | - | - | - | 189.39% | 256.46% | 149.92% |
| Announcement Date | 3/7/22 | 3/9/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
6.48
USD
Average target price
14.18
USD
Spread / Average Target
+118.86%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.86% | 749M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- PRME Stock
- Financials Prime Medicine, Inc.
